KR102913696B1 - 산화 스트레스 관련 피부 질환 및 피부 노화의 치료 및 산화 스트레스 관련 피부 질환의 진단을 위한 조성물 - Google Patents

산화 스트레스 관련 피부 질환 및 피부 노화의 치료 및 산화 스트레스 관련 피부 질환의 진단을 위한 조성물

Info

Publication number
KR102913696B1
KR102913696B1 KR1020217018454A KR20217018454A KR102913696B1 KR 102913696 B1 KR102913696 B1 KR 102913696B1 KR 1020217018454 A KR1020217018454 A KR 1020217018454A KR 20217018454 A KR20217018454 A KR 20217018454A KR 102913696 B1 KR102913696 B1 KR 102913696B1
Authority
KR
South Korea
Prior art keywords
roxp
acnes
skin
composition
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217018454A
Other languages
English (en)
Korean (ko)
Other versions
KR20210094576A (ko
Inventor
롤프 루드
Original Assignee
에스-바이오메딕 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스-바이오메딕 엔브이 filed Critical 에스-바이오메딕 엔브이
Publication of KR20210094576A publication Critical patent/KR20210094576A/ko
Application granted granted Critical
Publication of KR102913696B1 publication Critical patent/KR102913696B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
KR1020217018454A 2018-11-16 2019-11-15 산화 스트레스 관련 피부 질환 및 피부 노화의 치료 및 산화 스트레스 관련 피부 질환의 진단을 위한 조성물 Active KR102913696B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18206646 2018-11-16
EP18206646.4 2018-11-16
PCT/EP2019/081546 WO2020099663A1 (en) 2018-11-16 2019-11-15 Compositions for treating oxidative stress-associated skin diseases and skin ageing and diagnosis of oxidative stress-associated skin diseases

Publications (2)

Publication Number Publication Date
KR20210094576A KR20210094576A (ko) 2021-07-29
KR102913696B1 true KR102913696B1 (ko) 2026-01-16

Family

ID=64331864

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018454A Active KR102913696B1 (ko) 2018-11-16 2019-11-15 산화 스트레스 관련 피부 질환 및 피부 노화의 치료 및 산화 스트레스 관련 피부 질환의 진단을 위한 조성물

Country Status (12)

Country Link
US (1) US20220000762A1 (https=)
EP (1) EP3880304B8 (https=)
JP (1) JP7532361B2 (https=)
KR (1) KR102913696B1 (https=)
CN (1) CN113038959B (https=)
AU (1) AU2019380669B2 (https=)
BR (1) BR112021008496A2 (https=)
CA (1) CA3118524A1 (https=)
ES (1) ES2994459T3 (https=)
MX (1) MX2021005755A (https=)
PL (1) PL3880304T3 (https=)
WO (1) WO2020099663A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3025685T3 (en) 2014-06-17 2025-06-09 Crown Laboratories Inc Genetically modified bacteria and methods for genetic modification of bacteria
EP3285872A4 (en) 2015-04-20 2019-02-20 S-Biomedic NV METHOD AND COMPOSITIONS FOR CHANGING THE COMPOSITION OF SKIN MICROBIOMA WITH COMPLEX MIXTURES OF BACTERIAL BARS
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
KR102584057B1 (ko) 2016-10-19 2023-09-27 에스-바이오메딕 엔브이 박테리아 균주의 복합 혼합물을 사용하여 피부 마이크로바이옴의 조성을 변경하기 위한 방법 및 조성물
CA3183350A1 (en) 2020-06-23 2021-12-30 Thomas M. Hitchcock Probiotic skin formulations
CN116940330A (zh) * 2020-12-21 2023-10-24 南洋理工大学 短链脂肪酸作为去屑剂的用途
CN113219097B (zh) * 2021-01-15 2022-06-24 杭州海关技术中心 婴幼儿配方奶粉中肉碱对映体拆分和测定方法
CA3239122A1 (en) * 2021-12-17 2023-06-22 S-Biomedic A freeze-dried composition and preparation thereof
EP4197523A1 (en) * 2021-12-17 2023-06-21 DSM IP Assets B.V. A freeze-dried composition and preparation thereof
KR20240135644A (ko) * 2022-01-12 2024-09-11 에스-바이오메딕 엔브이 스킨 케어 조성물 및 이의 용도
CN115165819B (zh) * 2022-05-27 2024-08-09 天津科技大学 一种快速定量分析芦丁的荧光分子印迹光子晶体凝胶条的制备方法及应用
CN120173837B (zh) * 2025-05-21 2025-12-05 杭州微致生物科技有限公司 痤疮丙酸杆菌vb208基因编辑方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
JP2011037764A (ja) * 2009-08-11 2011-02-24 Shiseido Co Ltd 皮膚外用剤、美白剤、抗酸化剤および抗老化剤
FR2954140A1 (fr) * 2009-12-17 2011-06-24 Oreal Compositions cosmetiques ou dermatologiques a base de bacteriocines et de prebiotiques
ITPR20110035A1 (it) 2011-05-06 2012-11-07 Bormioli Rocco & Figlio Spa Capsula.
CN104364394B (zh) * 2012-03-17 2019-02-22 加州大学评议会 痤疮的快速诊断和个体化治疗
ITUA20162141A1 (it) 2016-03-31 2017-10-01 Bormioli Pharma Spa Capsula di chiusura
IT201600097495A1 (it) 2016-09-28 2018-03-28 Bormioli Pharma S R L Capsula con struttura di contenimento e rilascio di un prodotto
KR102584057B1 (ko) 2016-10-19 2023-09-27 에스-바이오메딕 엔브이 박테리아 균주의 복합 혼합물을 사용하여 피부 마이크로바이옴의 조성을 변경하기 위한 방법 및 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. Erturk et al., Plos One, 2018, 13, e0193754(2018.3.1.) 1부.*
M. Alhorn et al., Sci. Rep., 2016, 6, 36412(2016.11.2) 1부.*

Also Published As

Publication number Publication date
EP3880304B8 (en) 2024-11-20
EP3880304A1 (en) 2021-09-22
MX2021005755A (es) 2021-08-11
AU2019380669B2 (en) 2025-01-30
EP3880304C0 (en) 2024-10-16
WO2020099663A1 (en) 2020-05-22
KR20210094576A (ko) 2021-07-29
PL3880304T3 (pl) 2025-03-03
US20220000762A1 (en) 2022-01-06
EP3880304B1 (en) 2024-10-16
JP2022507616A (ja) 2022-01-18
CA3118524A1 (en) 2020-05-22
BR112021008496A2 (pt) 2021-08-10
CN113038959B (zh) 2024-09-13
JP7532361B2 (ja) 2024-08-13
CN113038959A (zh) 2021-06-25
AU2019380669A1 (en) 2021-05-20
ES2994459T3 (en) 2025-01-24

Similar Documents

Publication Publication Date Title
KR102913696B1 (ko) 산화 스트레스 관련 피부 질환 및 피부 노화의 치료 및 산화 스트레스 관련 피부 질환의 진단을 위한 조성물
Liu et al. Rhein attenuates cerebral ischemia-reperfusion injury via inhibition of ferroptosis through NRF2/SLC7A11/GPX4 pathway
Al-Madboly et al. Purification, characterization, identification, and anticancer activity of a circular bacteriocin from Enterococcus thailandicus
KR100844914B1 (ko) 탄력섬유형성의 불완전, 결여 혹은 해체로 인한 질병을제어하는 라이실 옥시다제의 동종효소의 활성 촉진
EP2178904B1 (en) Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
CN101627309A (zh) 核糖核酸酶家族的蛋白质的美容用途
Yang et al. GSTpi regulates VE-cadherin stabilization through promoting S-glutathionylation of Src
KR102043473B1 (ko) Ｓａｓｐａｓｅ－ｆｌｇ２ 복합체, 조정제, 및 용도
Qiao et al. Rosmarinic acid plus deferasirox inhibits ferroptosis to alleviate crush syndrome-related AKI via Nrf2/Keap1 pathway
Monoyios et al. An alliance of gel-based and gel-free proteomic techniques displays substantial insight into the proteome of a virulent and an attenuated Histomonas meleagridis strain
Yao et al. The potential benefits of Oreochromis mossambicus derived hydrophobic peptides in protecting the skin against UVA-induced damage
Stewart et al. Salivary antimicrobial peptide histatin-5 does not display Zn (II)-dependent or-independent activity against streptococci
Suwandecha et al. Novel antimicrobial peptide specifically active against Porphyromonas gingivalis
US20190060216A1 (en) Anti-pollution compositions containing bacillus coagulans
Sannasimuthu et al. Peroxiredoxin of Arthrospira platensis derived short molecule YT12 influences antioxidant and anticancer activity
Cui et al. Experimental and clinical applications of Chamaecyparis obtusa extracts in dry eye disease
US20200222294A1 (en) Vegfc production promoter
WO2013063656A1 (en) Gingipain inhibitory propeptides
León-García et al. Evaluation of cell wall damage by dimethyl sulfoxide in Candida species
Wan et al. Characterization of a novel streptococcal heme-binding protein SntA and its interaction with host antioxidant protein AOP2
HK40049609A (en) Compositions for treating oxidative stress-associated skin diseases and skin ageing
HK40049609B (en) Compositions for treating oxidative stress-associated skin diseases and skin ageing
Hu et al. The Rab1 GTPase of Sciaenops ocellatus modulates intracellular bacterial infection
KR20200053068A (ko) C-펩타이드를 유효성분으로 포함하는 미세먼지에 대한 피부보호용 화장료 조성물
Shao et al. Neospora caninum peroxiredoxin 1 is an essential virulence effector with antioxidant function

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)